First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors

• Main Authors: Mross K., Richly H., Fischer R., Scharr D., Büchert M., Stern A., Gille H., Audoly L.P., Scheulen M.E.
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2019
• Subjects: angiocal; bilirubin; gamma glutamyltransferase; gelatinase A; prs 050; unclassified drug; uric acid; vasculotropin A; vasculotropin inhibitor; angiocal protein; angiogenesis inhibitor; lipocalin; lipocalin 1; MMP2 protein, human; VEGFA protein, human; abdominal pain; adult; advanced cancer; aged; area under the curve; article; backache; bilirubin blood level; body weight disorder; cancer pain; cancer surgery; chill; clinical article; colorectal carcinoma; constipation; decreased appetite; dose response; drug clearance; drug distribution; drug dose escalation; drug exposure; drug half life; drug protein binding; drug safety; drug tolerability; dyspepsia; dyspnea; fatigue; female; fever; flatulence; gamma glutamyl transferase blood level; human; hypertension; hypotension; liver cell carcinoma; male; maximum plasma concentration; melanoma; nausea; neuroendocrine tumor; open study; pancreas carcinoma; peripheral edema; pharmacodynamics; phase 1 clinical trial; plasma concentration-time curve; recommended drug dose; repeated drug dose; rigor; single drug dose; small intestine perforation; solid tumor; systemic therapy; unspecified side effect; uric acid blood level; weight reduction; antagonists and inhibitors; blood; clinical trial; middle aged; Neoplasms; time; Adult; Aged; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Lipocalin 1; Lipocalins; Matrix Metalloproteinase 2; Middle Aged; Time Factors; Vascular Endothelial Growth Factor A
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/161444
• Institution: National University of Singapore

10.1371/journal.pone.0083232